logo

For the Inventor, By the Inventor

North Caldwell, NJ, United States of America

Enrico G Baggiolini

This inventor holds 28 USPTO granted patents, plus 1 CIPO patent, primarily in Vitamin D Compounds. Top assignee: Hoffmann-La Roche Inc.. Active years: 1976-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Enrico G Baggiolini. Retrieved from https://idiyas.com/inventor/enrico-g-baggiolini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28

% Patents Active = 100.0


Average Co-Inventor Count = 3.4

ph-index = 8

Forward Citations = 233(Granted Patents)


Location History:

  • Nutley, NJ (US) (1976 - 1982)
  • Bloomfield, NJ (US) (1980 - 1983)
  • North Caldwell, NJ (US) (1985 - 1993)

Company Filing History:

goldMedal28 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents

Years Active: 1976-1993

Loading Chart...
Loading Chart...
Areas of Expertise:
Vitamin D Compounds
Deuterated Analogs
Synthesis Processes
Biotin Intermediates
Fluorinated Compounds
Cholecalciferol Derivatives
Ergocalciferol
Trifluorinated Compounds
Hexahydro Thieno
Isoxazolines
Trihydroxy Compounds
Metabolite Derivatives
28 patents (USPTO):Explore Patents
1. 5247123 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1993-09-21),
2. 5149846 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1992-09-22),
3. 5120722 - Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating (1992-06-09),
4. 5110958 - Compounds, process and intermediates (1992-05-05),
5. 5039671 - Trifluorinated-1.alpha.,25S-dihydroxy vitamin D3 compounds (1991-08-13),
6. 4906785 - Novel trifluorinated vitamin D3 intermediates (1990-03-06),
7. 4898855 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1990-02-06),
8. 4804502 - Vitamin D compounds (1989-02-14),
9. 4632784 - Process for the preparation of (1986-12-30),
10. 4613594 - Fluorinated vitamin D.sub.3 compounds (1986-09-23),
11. 4612308 - 25,26-Dehydro-1.alpha.,23(S,R)-dihydroxycholecalciferol and its epimers (1986-09-16),
12. 4595776 - Synthesis of 1.alpha.,25-dihydroxyergocalciferol (1986-06-17),
13. 4594432 - Process for the synthesis of 1.alpha.,23(S),25-trihydroxycholecalciferol (1986-06-10),
14. 4508651 - Synthesis of 1.alpha.,25-dihydroxyergocalciferol (1985-04-02),
15. 4382031 - Intermediates for the preparation of biotin (1983-05-03),

Title: Enrico G. Baggiolini: Innovator in Vitamin D Analog Research

Introduction

Enrico G. Baggiolini, based in North Caldwell, NJ, is a prominent inventor known for his contributions to the field of pharmaceutical sciences. With an impressive portfolio of 28 patents, Baggiolini has focused on innovations that aim to improve health outcomes, particularly in the treatment of osteoporosis and skin conditions.

Latest Patents

Among his latest patents, Baggiolini has developed deuterated analogs of 1,25-dihydroxycholecalciferol. This invention encompasses processes and intermediates for the preparation of these vitamin D analogs. The end products are particularly beneficial for treating osteoporosis, as well as cutaneous inflammations such as psoriasis and contact dermatitis. The innovative nature of this research positions Baggiolini at the forefront of therapeutic advancements in vitamin D applications.

Career Highlights

Baggiolini's career is marked by his role at Hoffmann-La Roche Inc., a renowned global healthcare company committed to innovative pharmaceuticals. His work has significantly impacted the pharmaceutical landscape, contributing to the understanding and application of vitamin D in various therapeutic contexts.

Collaborations

Throughout his career, Baggiolini has collaborated with esteemed colleagues such as Milan R. Uskokovic and Hsi L. Lee. These collaborations have allowed for the cross-pollination of ideas and expertise, fostering advancements in the research and development of vitamin D analogs.

Conclusion

Enrico G. Baggiolini exemplifies the spirit of innovation in the pharmaceutical industry. His advancements in deuterated vitamin D analogs not only highlight his expertise but also contribute to significant improvements in therapeutic options for patients suffering from osteoporosis and skin ailments. As research continues, Baggiolini's work will likely remain influential in shaping future healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…